<DOC>
	<DOCNO>NCT02299505</DOCNO>
	<brief_summary>A Phase I study assess systemic exposure , effiacy , safety 450 mg ceritinib take low-fat meal 600 mg ceritinib take low-fat meal compare 750 mg ceritinib take fasted state adult patient ALK rearrange ( ALK-positive ) metastatic non-small cell lung cancer ( NSCLC )</brief_summary>
	<brief_title>Pharmacokinetic Safety Study Lower Doses Ceritinib Taken With Low-fat Meal Versus 750 mg Ceritinib Fasted State Adult Patients With ( ALK-positive ) Metastatic Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>Inclusion : 1 . Histologically cytologically confirm diagnosis stage IIIB ( candidate definitive multimodality therapy ) IV ALKpositive NSCLC . 2 . Patients may receive one prior treatment regimen crizotinib ( ALK inhibitor exclude ) . 3 . Patients may receive prior chemotherapy , biologic therapy , investigational agent . ALK inhibitor crizotinib exclude . 4 . Patient World Health Organization ( WHO ) performance status 02 . Exclusion : 1 . Prior treatment ALK inhibitor crizotinib . 2 . History carcinomatous meningitis . 3 . Presence history malignant disease ALKpositive advance tumor diagnose and/or require therapy within past 3 year . 5 . Clinically significant , uncontrolled heart disease and/or recent cardiac event ( within 6 month ) 6 . Patient history interstitial lung disease interstitial pneumonitis , include clinically significant radiation pneumonitis ( i.e. , affecting activity daily live require therapeutic intervention ) . 7 . Patient severe , acute , chronic medical condition 8 . Patient currently receive treatment warfarin sodium ( CoumadinÂ® ) coumarinderivative anticoagulant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>LDK378</keyword>
	<keyword>ceritinib</keyword>
	<keyword>Alk+</keyword>
	<keyword>Alk positive</keyword>
	<keyword>NSCLC</keyword>
	<keyword>lung Cancer</keyword>
</DOC>